BACKGROUND: @entity3131 ( @entity15795 ) is a novel anti-fibrotic agent that can prevent and even reverse extracellular matrix accumulation in several organs, as shown by experimental and clinical studies. @entity1695 ( @entity1695 ) is a well-characterized model of experimental @entity8 culminating in tubulointerstitial @entity82 . METHODS: @entity1695 or sham-operated @entity35 were administered @entity15795 (500 mg/kg/day) in their food for 21 days to examine the effect on collagen production. The renal function was measured in the kidney after release of obstruction which had been maintained for one week to examine the effects of @entity15795 on restoration after @entity8 . RESULTS: The collagen content detected by @entity720 progressively increased in kidney with @entity1695 for 21 days. These increases were significantly suppressed by administration of @entity15795 . @entity15795 had no effect on collagen production in sham-operated @entity35 . Expression of mRNA for type IV and I collagen and matrix metalloproteinase-2 in the cortex increased with @entity1695 , but was inhibited by @entity15795 treatment. The levels of cortical transforming growth factor-beta ( @entity1810 ) mRNA progressively rose with @entity1695 for 21 days, but this increase also could be suppressed by @entity15795 . Inulin clearance of the obstructed kidney was markedly depressed and remained low at five weeks after release. A progressive increase in @entity720 content was also observed in the post-obstructed kidney despite the release of obstruction. Administration of @entity15795 following the release not only attenuated collagen accumulation, but also induced recovery of the @entity8 . CONCLUSIONS: These results demonstrate that @entity15795 can attenuate both @entity8 and @entity8 in this model, and suggest that @entity15795 can be clinically useful for preventing progressive, irreversible @entity177 .

@entity3131 improves renal function and XXXX in the post-obstructed kidney.

@entity8 :: ('MESH:D007674', 'Disease') :: ['renal fibrosis', 'renal damage', 'renal disease', 'renal dysfunction', 'impaired renal function'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity15795 :: ('CHEBI:31263', 'Chemical') :: ['PFD'] @entity1695 :: ('MESH:D014517', 'Disease') :: ['Unilateral ureteral obstruction', 'UUO'] @entity3131 :: ('MESH:C093844', 'Chemical') :: ['Pirfenidone'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure'] @entity720 :: ('CHEBI:18095', 'Chemical') :: ['hydroxyproline'] @entity1810 :: ('59086(Tax:10116)', 'Gene') :: ['TGF-beta'] @entity35 :: ('10116', 'Species') :: ['rats']
@entity82 :: (MESH:D005355,Disease) :: ['fibrosis']
